MedWatch

A part of Watch Media

Fertin Pharma's bottom line suffers as bonuses and postponed product launches bite

The top-line results are unchanged for Fertin Pharma, but the bottom line has taken a hit. Delayed product launches and a bonus paid to all employees have made their mark on the books.

Photo: Fertin Pharma / PR
by christian bundgaard, translated by catherine brett

Fertin Pharma has had an eventful 2021.

This much is clear from the company’s latest accounting report, which details an essentially unchanged top-line result of DKK 933m (USD 131m) in 2021 compared to DKK 991m (USD 139m) in 2020, but a dramatic drop on the bottom line.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

  1. Top news from MedWatch this week
  2. ALK's tablet trial in Ukraine set to continue
  3. US biotech firm ramps up collaboration with Genmab after dropping drug candidate
  4. Genmab postpones crucial cancer candidate decision following Abbvie exit
  5. ALK to exit Turkish market: "It's bad business if all we get is peanuts"
  6. Genmab to measure growth hope against bestseller
  7. Genmab says new arbitration builds on a straightforward question
  8. Zealand Pharma's deficit grows in quarter with product divestment
  9. Analyst: Upgraded ALK sales guidance could still be beaten
  10. ALK fears politicians will force pharma industry to foot pandemic bill
  11. GN, Sonova advance with Veterans Affairs in July – Demant, WSA retreat
  12. Europe will have to wait for Ascendis Pharma's weekly growth hormone
  13. Novo turns to new factories to boost supply of obesity drug
  14. Abbvie withdraws from cancer candidate collaboration with Genmab
  15. Organizational expansion sends Genmab costs soaring

See all

Job

See all jobs

See all jobs